환자 증상에 대한 통합 종양학
환자 증상 및 삶의 질에 대한 통합 종양학 프로그램의 영향 조사: 전향적 실용 레지스트리 프로토콜 연구
The use of complementary and integrative medicine (CIM) among oncology patients is widespread, with a large body of research-based evidence supporting the ability of these therapies to alleviate symptoms related to cancer and its treatment. Organizations such as the American Society for Clinical Oncology and the European Society for Medical Oncology have included CIM modalities in their treatment guidelines, and many of today's leading cancer centers include CIM in their supportive care service. The proposed study will prospectively examine the impact of a CIM treatment program on the symptom burden, quality of life and function of patients undergoing active oncology treatment.
A total of 750 patients will undergo an integrative oncologist (IP) consultation followed by a series of 8 CIM treatments consisting of either acupuncture or touch-related therapies (reflexology, Shiatsu, Tuina, etc.) with the goal of relieving their symptoms. Patients will be allocated to one of the two study treatment arms: the "Patient-Preference Arm", for patients who specify their preference for either acupuncture or touch therapy; and the "Randomized Treatment Arm", for those with no preference, to be randomly allocated to either the acupuncture or touch-therapy subgroup. Patients will be asked to complete the following study questionnaires before and after the treatment regimen: the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30); the Edmonton Symptom Assessment System (ESAS); and the Measure Yourself Concerns and Wellbeing (MYCAW) tool. The primary study outcome will be the change in EORTC Global Health-Status / Quality of Life scores, from pre- to post-treatment. Secondary study outcomes will include EORTC QLQ-C30 functional and symptom scales, single items assessing additional symptoms commonly reported by cancer patients, and perceived financial impact of the disease; ESAS severity scores for 10 quality-of life related items; and MYCAW severity scores for the 2 most significant symptoms, as well as post-treatment narratives. Other secondary outcomes to be assessed include the safety of the study treatments (adverse effects); adherence to conventional treatment regimen; and narratives from the patient's informal caregiver (spouse, parent/child, sibling, friend, etc.).
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 해당 없음
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Noah Samuels, M.D.
- 전화번호: 972-26666395
- 이메일: noahs@szmc.org.il
연구 장소
-
-
-
Jerusalem, 이스라엘, 7791031
- 모병
- Institute of Oncology, Shaare Zedek Medical Center
-
연락하다:
- Noah Samuels, M.D.
- 전화번호: 026666395
- 이메일: noahs@szmc.org.il
-
부수사관:
- Nathan Cherny, M.D.
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- age ≥ 18 years
- undergoing active oncology treatment
- fully understand the study plan
- agree to sign the study informed consent form.
Exclusion Criteria:
- not fulfilling all of the study criteria
- not interested in attending all 8 weekly CIM treatments sessions
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
활성 비교기: Patient Preference Arm - Acupuncture
Patients who specify their preference for acupuncture |
Acupuncture points will be selected on an individualized and symptom-directed basis, with the incorporation of points shown in clinical research to be effective for specific symptoms Touch therapies are to include Reflexology, Shiatsu and Therapeutic Touch |
|
활성 비교기: Randomized Treatment Arm - Acupuncture
Patients with no preference to be randomly allocated to acupuncture (vs. touch-therapy); ratio 1:1 |
Acupuncture points will be selected on an individualized and symptom-directed basis, with the incorporation of points shown in clinical research to be effective for specific symptoms |
|
활성 비교기: Patient Preference Arm - Touch Therapy
Patients who specify their preference for touch therapy |
Acupuncture points will be selected on an individualized and symptom-directed basis, with the incorporation of points shown in clinical research to be effective for specific symptoms Touch therapies are to include Reflexology, Shiatsu and Therapeutic Touch |
|
활성 비교기: Randomized Treatment Arm - Touch Therapy
Patients with no preference to be randomly allocated to touch therapy (vs. acupuncture); ratio 1:1 |
Touch therapies are to include Reflexology, Shiatsu and Therapeutic Touch |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
EORTC QLQ-C30 global health status / QoL scale
기간: 8 weeks
|
Change from baseline to the end of the 8-week integrative treatment program |
8 weeks
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
EORTC QLQ-C30 global health status / QoL scale
기간: 16 weeks
|
Change from baseline and 8-week assessment to 16 week follow-up |
16 weeks
|
|
EORTC QLQ-C30 - additional outcomes
기간: From baseline to 8- (end of treatment program) and 16-week (post-program) assessment
|
Change in functional and symptom scores |
From baseline to 8- (end of treatment program) and 16-week (post-program) assessment
|
|
ESAS symptom severity scores
기간: From baseline to 8- (end of treatment program) and 16-week (post-program) assessment
|
Change in severity scores for 10 quality-of life related items |
From baseline to 8- (end of treatment program) and 16-week (post-program) assessment
|
|
MYCAW symptom severity scores
기간: From baseline to 8- (end of treatment program) and 16-week (post-program) assessment
|
Change in severity scores for the 2 most significant symptoms, as well as post-treatment narratives |
From baseline to 8- (end of treatment program) and 16-week (post-program) assessment
|
|
Frequency of adverse effects
기간: At the end of the series of 8 weekly CIM treatment sessions (≤ 2 weeks after the last treatment session); after 16 weeks from baseline.
|
Any reported adverse events taking place during the study period which are considered to have possibly/probably resulted from the CIM intervention |
At the end of the series of 8 weekly CIM treatment sessions (≤ 2 weeks after the last treatment session); after 16 weeks from baseline.
|
|
Adherence to conventional oncology treatment regimen
기간: At 16 weeks from baseline.
|
Adherence to oncology treatment to be measured using the Relative Dose Intensity (RDI) calculation |
At 16 weeks from baseline.
|
|
Caregiver expectations
기간: At baseline
|
Narratives from the patient's informal caregiver (spouse, parent/child, sibling, friend, etc.). |
At baseline
|
공동 작업자 및 조사자
간행물 및 유용한 링크
일반 간행물
- Samuels N, Oberbaum M, Ben-Arye E. Expectations of Patients and Their Informal Caregivers from an Integrative Oncology Consultation. Integr Cancer Ther. 2021 Jan-Dec;20:1534735421990080. doi: 10.1177/1534735421990080.
- Samuels N, Ben-Arye E. Integrative Approaches to Chemotherapy-Induced Peripheral Neuropathy. Curr Oncol Rep. 2020 Feb 11;22(3):23. doi: 10.1007/s11912-020-0891-2.
- Ben-Arye E, Dahly H, Keshet Y, Dagash J, Samuels N. Providing integrative care in the pre-chemotherapy setting: a pragmatic controlled patient-centered trial with implications for supportive cancer care. J Cancer Res Clin Oncol. 2018 Sep;144(9):1825-1833. doi: 10.1007/s00432-018-2700-y. Epub 2018 Jul 6.
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- INTEGR.ONCOL.REGIST-2021
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .